TOGETHER

Vyxeos is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos is the first chemotherapy to significantly increase overall survival vs 7+3 in patients with high risk* AML2

TOGETHER

Vyxeos is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos is the first chemotherapy to significantly increase overall survival vs 7+3 in patients with high risk* AML2

Utilising advanced dual drug liposomal technology to optimise the delivery of daunorubicin and cytarabine to significantly improve efficacy1,2

https://vyxeos.eu/wp-content/uploads/2018/08/Moa_16x9_screenshot.png

Vyxeos Mechanism of Action

Vyxeos significantly increases overall survival compared to 7+3 in patients with high-risk* AML2

https://vyxeos.eu/wp-content/uploads/2018/08/3_VXYEOS_GRAPH_16X9_TRANSPLANT_DATA_180828-1.png

Vyxeos Phase 3 Study

Vyxeos offers a 90-minute infusion schedule3

https://vyxeos.eu/wp-content/uploads/2018/08/11_VXYEOS_GRAPH_16X9_ADMINISTRATION_180731-1.png

Preparing Vyxeos

Vyxeos® is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).3

*High risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13):1317-32.
  2. Lancet JE et al. 2018. J Clin Oncol 2018. Published online ahead of print. doi: 10.1200/JCO.2017.77.6112
  3. VYXEOS Summary of product characteristics

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

EURW-INTVYX-0020a(1) | September 2019